The Mef2 transcription network is disrupted in myotonic dystrophy heart tissue, dramatically altering miRNA and mRNA expression

Cell Reports

Volumn 6, Issue 2, 2014, Pages 336-345

  Kalsotra, Auinash ^a,b   Singh, Ravi K ^a   Gurha, Priyatansh ^a,c   Ward, Amanda J ^a,d   Creighton, Chad J ^a   Cooper, Thomas A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA; MYOCYTE ENHANCER FACTOR 2;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEART ARRHYTHMIA; HEART MUSCLE FIBROSIS; HUMAN; HUMAN TISSUE; MALE; MEF2A GENE; MEF2C GENE; MIDDLE AGED; MOLECULAR PATHOLOGY; MOUSE; MYOTONIC DYSTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; YOUNG ADULT;

ADULT; ANIMALS; CASE-CONTROL STUDIES; FEMALE; GENE REGULATORY NETWORKS; HUMANS; MALE; MEF2 TRANSCRIPTION FACTORS; MICE; MICRORNAS; MIDDLE AGED; MYOCARDIUM; MYOTONIC DYSTROPHY; RNA, MESSENGER;

EID: 84895907629     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2013.12.025     Document Type: Article

References (42)

1. Bachinski L.L., Sirito M., Böhme M., Baggerly K.A., Udd B., Krahe R. Altered MEF2 isoforms in myotonic dystrophy and other neuromuscular disorders. Muscle Nerve 2010, 42:856-863.
2. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
3. Creighton C.J., Casa A., Lazard Z., Huang S., Tsimelzon A., Hilsenbeck S.G., Osborne C.K., Lee A.V. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J.Clin. Oncol. 2008, 26:4078-4085.
4. Duisters R.F., Tijsen A.J., Schroen B., Leenders J.J., Lentink V., van der Made I., Herias V., van Leeuwen R.E., Schellings M.W., Barenbrug P., et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ. Res. 2009, 104:170-178. 6p, 178.
5. Fernandez-Costa J.M., Garcia-Lopez A., Zuñiga S., Fernandez-Pedrosa V., Felipo-Benavent A., Mata M., Jaka O., Aiastui A., Hernandez-Torres F., Aguado B., et al. Expanded CTG repeats trigger miRNA alterations in Drosophila that are conserved in myotonic dystrophy type 1 patients. Hum. Mol. Genet. 2013, 22:704-716.
6. Groh W.J., Groh M.R., Saha C., Kincaid J.C., Simmons Z., Ciafaloni E., Pourmand R., Otten R.F., Bhakta D., Nair G.V., et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N.Engl. J. Med. 2008, 358:2688-2697.
7. Heatwole C., Bode R., Johnson N., Quinn C., Martens W., McDermott M.P., Rothrock N., Thornton C., Vickrey B., Victorson D., Moxley R. Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1). Neurology 2012, 79:348-357.
8. Ieda M., Fu J.D., Delgado-Olguin P., Vedantham V., Hayashi Y., Bruneau B.G., Srivastava D. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010, 142:375-386.
9. Kalsotra A., Xiao X., Ward A.J., Castle J.C., Johnson J.M., Burge C.B., Cooper T.A. A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc. Natl. Acad. Sci. USA 2008, 105:20333-20338.
10. Kalsotra A., Wang K., Li P.F., Cooper T.A. MicroRNAs coordinate an alternative splicing network during mouse postnatal heart development. Genes Dev. 2010, 24:653-658.
11. Kanadia R.N., Johnstone K.A., Mankodi A., Lungu C., Thornton C.A., Esson D., Timmers A.M., Hauswirth W.W., Swanson M.S. A muscleblind knockout model for myotonic dystrophy. Science 2003, 302:1978-1980.
12. Koshelev M., Sarma S., Price R.E., Wehrens X.H., Cooper T.A. Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1. Hum. Mol. Genet. 2010, 19:1066-1075.
13. Kuyumcu-Martinez N.M., Wang G.S., Cooper T.A. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol. Cell 2007, 28:68-78.
14. Lazarus A., Varin J., Babuty D., Anselme F., Coste J., Duboc D. Long-term follow-up of arrhythmias in patients with myotonic dystrophy treated by pacing: a multicenter diagnostic pacemaker study. J.Am. Coll. Cardiol. 2002, 40:1645-1652.
15. Lee J.E., Cooper T.A. Pathogenic mechanisms of myotonic dystrophy. Biochem. Soc. Trans. 2009, 37:1281-1286.
16. Lee J.E., Bennett C.F., Cooper T.A. RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1. Proc. Natl. Acad. Sci. USA 2012, 109:4221-4226.
17. Lin X., Miller J.W., Mankodi A., Kanadia R.N., Yuan Y., Moxley R.T., Swanson M.S., Thornton C.A. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum. Mol. Genet. 2006, 15:2087-2097.
18. Liu N., Williams A.H., Kim Y., McAnally J., Bezprozvannaya S., Sutherland L.B., Richardson J.A., Bassel-Duby R., Olson E.N. An intragenic MEF2-dependent enhancer directs muscle-specific expression of microRNAs 1 and 133. Proc. Natl. Acad. Sci. USA 2007, 104:20844-20849.
19. López Castel A., Nakamori M., Tomé S., Chitayat D., Gourdon G., Thornton C.A., Pearson C.E. Expanded CTG repeat demarcates a boundary for abnormal CpG methylation in myotonic dystrophy patient tissues. Hum. Mol. Genet. 2011, 20:1-15.
20. Molkentin J.D., Olson E.N. Combinatorial control of muscle development by basic helix-loop-helix and MADS-box transcription factors. Proc. Natl. Acad. Sci. USA 1996, 93:9366-9373.
21. Moseley M.L., Zu T., Ikeda Y., Gao W., Mosemiller A.K., Daughters R.S., Chen G., Weatherspoon M.R., Clark H.B., Ebner T.J., et al. Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. Nat. Genet. 2006, 38:758-769.
22. Nazarian S., Bluemke D.A., Wagner K.R., Zviman M.M., Turkbey E., Caffo B.S., Shehata M., Edwards D., Butcher B., Calkins H., et al. QRS prolongation in myotonic muscular dystrophy and diffuse fibrosis on cardiac magnetic resonance. Magn. Reson. Med. 2010, 64:107-114.
23. Pelargonio G., Dello Russo A., Sanna T., De Martino G., Bellocci F. Myotonic dystrophy and the heart. Heart 2002, 88:665-670.
24. Perbellini R., Greco S., Sarra-Ferraris G., Cardani R., Capogrossi M.C., Meola G., Martelli F. Dysregulation and cellular mislocalization of specific miRNAs in myotonic dystrophy type 1. Neuromuscul. Disord. 2011, 21:81-88.
25. Phillips M.F., Harper P.S. Cardiac disease in myotonic dystrophy. Cardiovasc. Res. 1997, 33:13-22.
26. Potthoff M.J., Olson E.N. MEF2: a central regulator of diverse developmental programs. Development 2007, 134:4131-4140.
27. Qian L., Huang Y., Spencer C.I., Foley A., Vedantham V., Liu L., Conway S.J., Fu J.D., Srivastava D. Invivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 2012, 485:593-598.
28. Rau F., Freyermuth F., Fugier C., Villemin J.P., Fischer M.C., Jost B., Dembele D., Gourdon G., Nicole A., Duboc D., et al. Misregulation of miR-1 processing is associated with heart defects in myotonic dystrophy. Nat. Struct. Mol. Biol. 2011, 18:840-845.
29. Salehi L.B., Bonifazi E., Stasio E.D., Gennarelli M., Botta A., Vallo L., Iraci R., Massa R., Antonini G., Angelini C., Novelli G. Risk prediction for clinical phenotype in myotonic dystrophy type 1: data from 2,650 patients. Genet. Test. 2007, 11:84-90.
30. Savkur R.S., Philips A.V., Cooper T.A. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat. Genet. 2001, 29:40-47.
31. Sicot G., Gourdon G., Gomes-Pereira M. Myotonic dystrophy, when simple repeats reveal complex pathogenic entities: new findings and future challenges. Hum. Mol. Genet. 2011, 20(R2):R116-R123.
32. Sohal D.S., Nghiem M., Crackower M.A., Witt S.A., Kimball T.R., Tymitz K.M., Penninger J.M., Molkentin J.D. Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. Circ. Res. 2001, 89:20-25.
33. Sovari A.A., Bodine C.K., Farokhi F. Cardiovascular manifestations of myotonic dystrophy-1. Cardiol. Rev. 2007, 15:191-194.
34. Thum T., Gross C., Fiedler J., Fischer T., Kissler S., Bussen M., Galuppo P., Just S., Rottbauer W., Frantz S., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456:980-984.
35. Timchenko L. Molecular mechanisms of muscle atrophy in myotonic dystrophies. Int. J. Biochem. Cell Biol. 2013, 45:2280-2287.
36. Timchenko N.A., Cai Z.J., Welm A.L., Reddy S., Ashizawa T., Timchenko L.T. RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J.Biol. Chem. 2001, 276:7820-7826.
37. Udd B., Krahe R. The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol. 2012, 11:891-905.
38. van Rooij E., Sutherland L.B., Thatcher J.E., DiMaio J.M., Naseem R.H., Marshall W.S., Hill J.A., Olson E.N. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl. Acad. Sci. USA 2008, 105:13027-13032.
39. Wang G.S., Kearney D.L., De Biasi M., Taffet G., Cooper T.A. Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy. J.Clin. Invest. 2007, 117:2802-2811.
40. Wheeler T.M., Thornton C.A. Myotonic dystrophy: RNA-mediated muscle disease. Curr. Opin. Neurol. 2007, 20:572-576.
41. Zhao Y., Ransom J.F., Li A., Vedantham V., von Drehle M., Muth A.N., Tsuchihashi T., McManus M.T., Schwartz R.J., Srivastava D. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007, 129:303-317.
42. Zu T., Gibbens B., Doty N.S., Gomes-Pereira M., Huguet A., Stone M.D., Margolis J., Peterson M., Markowski T.W., Ingram M.A., et al. Non-ATG-initiated translation directed by microsatellite expansions. Proc. Natl. Acad. Sci. USA 2011, 108:260-265.